On Nov 15, major Wall Street analysts update their ratings for $Tarsus Pharmaceuticals (TARS.US)$, with price targets ranging from $65 to $84.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and maintains the target price at $68.
Oppenheimer analyst Francois Brisebois maintains with a buy rating, and adjusts the target price from $63 to $65.
H.C. Wainwright analyst Oren Livnat maintains with a buy rating, and adjusts the target price from $61 to $73.
LifeSci Capital analyst Cory Jubinville, PhD maintains with a buy rating, and adjusts the target price from $67 to $84.
Furthermore, according to the comprehensive report, the opinions of $Tarsus Pharmaceuticals (TARS.US)$'s main analysts recently are as follows:
Tarsus Pharmaceuticals' third-quarter EPS exceeded expectations, with a significant beat on Xdemvy net product sales reaching $48.1M, though the number of vials dispensed aligned with forecasts. The company's discussion during the call was centered on a more positive forecast for Xdemvy in the fourth quarter and subsequent periods, following the expansion of the sales team.
Tarsus Pharmaceuticals reported a third-quarter topline of $48.1M, surpassing both the anticipated $44.3M and the consensus estimate of $43M, showcasing a robust growth of 40%. The company's advancements with target ECPs are noteworthy, with over 13,000 ECPs already prescribing Xdemvy. It's expected that Tarsus' efforts will continue to propel Xdemvy's growth. Positive data concerning MGD has been met with enthusiasm, and there is an anticipation for the company's strategic approach to commercialization.
Here are the latest investment ratings and price targets for $Tarsus Pharmaceuticals (TARS.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.